Advertisement
+ News Categories + Corporate Categories + Report Categories

Superficial keratectomy, PTK, and mitomycin C as a combined treatment option for Salzmann's nodular degeneration: a follow-up of eight eyes.

Summary


PURPOSE:
To analyze the treatment outcomes (safety and efficacy) of manual superficial keratectomy, phototherapeutic keratectomy (PTK), and intraoperative application of mitomycin C (MMC) for Salzmann nodular degeneration (SND).
METHODS:
In this retrospective study, we analyzed the records of eight eyes of five patients with Salzmann nodular degeneration (SND) who were treated between December 2006 and May 2008 at the University Eye Clinic Hamburg, Eppendorf, Germany. This case study includes data previously published within a single case report. Patients were followed-up pre- and postoperatively by slit-lamp biomicroscopy, digital photography, and corneal topography. All of the eight eyes were followed-up for at least 12 months, whereas in four eyes, follow-up was done for more than 24 months. PTK was performed with a 193-nm Ar-F excimer laser (Allegretto 200; WaveLight AG, Erlangen, Germany) within a 7-mm optical zone. Mitomycin C 0.02% was applied after PTK for 30 s. Postoperatively, a therapeutic contact lens was administered until corneal epithelial healing, which occurred usually at the forth postoperative day. Then local steroid therapy (prednisolone 1%) eye drops fours times per day was given for the following 4 weeks.
RESULTS:
Mean BCVA preoperatively was 0.61 logMAR (i.e., 20/80 Snellen equivalent or 0.25 decimal). There was a significant increase of BCVA by average of four reading lines (far distance) up to ten reading lines (p < 0.001). Mean BCVA postoperatively was 0.2 logMAR (i.e., 20/32 Snellen equivalent or 0.63 decimal). Treatment of SND led to a dramatic reduction of hyperopia (myopic shift) corresponding to a marked increase of best-corrected visual acuity (BCVA). Preoperatively documented hyperopic progression was stopped and refraction remained stable during the follow-up period in all eyes. Corneal topography showed regular astigmatism. During follow-up after treatment, the corneas appeared clear on slit-lamp examination.
CONCLUSIONS:
Our follow-up and the small treatment numbers are not sufficient to finally prove the superiority of the combined treatment modality (superficial keratectomy, PTK, and MMC) for SND, but the results of our study are promising. Longer follow-up and a larger cohort are warranted for proving MMC to be an effective, successful, and safe method in the armamentarium for treating and preventing Salzmann degeneration.

Affiliation

Department of Ophthalmology at Josef Carree, Outpatients Clinic of St. Josef and St. Elisabeth Hospital, Ruhr University Bochum, Gudrunstr. 56, 44791, Bochum, Germany, Dr.Khaireddin@gmx.de.

Journal Details

Name: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Opht
ISSN: 1435-702X
Pages:

Links

MESH Definitions

Porfiromycin

Toxic antibiotic of the mitomycin group, obtained from MITOMYCIN and also from Streptomyces ardus and other species. It is proposed as an antineoplastic agent, with some antibiotic properties.

Carbazilquinone

An alkylating agent structurally similar to MITOMYCIN and found to be effective in the treatment of leukemia and various other neoplasms in mice. It causes leukemia and thrombocytopenia in almost all human patients.

Severe Combined Immunodeficiency

Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID).

Combined Modality Therapy

The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.

Compassionate Use Trials

Providing an investigational therapy to a patient who is not eligible to receive that therapy in a clinical trial, but who has a serious or life-threatening illness for which other treatments are not available. Compassionate use trials allow patients to receive promising but not yet fully studied or approved therapies when no other treatment option exists. Also called expanded access trial.

 PubMed Articles 4884 Associated PubMed Articles :: Search

 Clinical Trials 1243 Associated Clinical Trials :: Search